Additionally, a study published by Chen et al. evaluated the expression of a short non-functioning form of OSMRβ, dubbed OSMRs, that is highly expressed in lung cancer patients, and acts a decoy receptor for OSM and thus resulting in mitigating OSMs oncogenic capabilities (181). The gene discussed is OSMR; the disease is lung carcinoma.